Today: Today, Aegis Begins Coverage on Momenta Pharmaceuticals Inc. (MNTA)

Today, Aegis Begins Coverage on Momenta Pharmaceuticals Inc. (MNTA)

Aegis started coverage on shares of Momenta Pharmaceuticals Inc. (NASDAQ:MNTA) in a research note issued to investors on Tuesday morning. The firm issued a hold rating and a $15.00 price objective on the biotechnology company’s stock.

MNTA has been the subject of several other reports. Zacks Investment Research raised shares of Momenta Pharmaceuticals from a hold rating to a buy rating and set a $14.00 price objective for the company in a report on Thursday, October 13th. Maxim Group cut shares of Momenta Pharmaceuticals from a hold rating to a sell rating and set a $6.00 price objective for the company. in a report on Wednesday, September 7th. Cowen and Company reissued a hold rating on shares of Momenta Pharmaceuticals in a report on Sunday, August 7th. Brean Capital set a $19.00 price objective on shares of Momenta Pharmaceuticals and gave the company a buy rating in a report on Friday, August 5th. Finally, JPMorgan Chase & Co. decreased their price objective on shares of Momenta Pharmaceuticals from $21.00 to $15.00 and set an overweight rating for the company in a report on Friday, August 5th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and six have given a buy rating to the company’s stock. The stock presently has a consensus rating of Buy and an average price target of $16.10.

Shares of Momenta Pharmaceuticals (NASDAQ:MNTA) opened at 14.10 on Tuesday. Momenta Pharmaceuticals has a 1-year low of $7.86 and a 1-year high of $18.26. The stock’s market capitalization is $972.29 million. The firm has a 50-day moving average of $12.27 and a 200 day moving average of $11.65.

Momenta Pharmaceuticals (NASDAQ:MNTA) last released its quarterly earnings data on Wednesday, November 2nd. The biotechnology company reported ($0.26) earnings per share for the quarter, beating the consensus estimate of ($0.29) by $0.03. Momenta Pharmaceuticals had a negative net margin of 93.75% and a negative return on equity of 26.55%. The firm earned $299.14 million during the quarter, compared to analysts’ expectations of $25.68 million. During the same period in the previous year, the company earned ($0.44) earnings per share. The firm’s quarterly revenue was up 2067.7% on a year-over-year basis. Analysts predict that Momenta Pharmaceuticals will post ($1.16) EPS for the current year.

In other Momenta Pharmaceuticals news, President Craig A. Wheeler sold 5,880 shares of the company’s stock in a transaction that occurred on Tuesday, November 22nd. The shares were sold at an average price of $13.68, for a total value of $80,438.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 6.10% of the stock is currently owned by company insiders.

Several institutional investors have recently bought and sold shares of the company. Pacad Investment Ltd. bought a new position in shares of Momenta Pharmaceuticals during the second quarter worth $103,000. Jane Street Group LLC bought a new position in shares of Momenta Pharmaceuticals during the second quarter worth $109,000. Dynamic Technology Lab Private Ltd bought a new position in shares of Momenta Pharmaceuticals during the second quarter worth $109,000. Profund Advisors LLC bought a new position in shares of Momenta Pharmaceuticals during the third quarter worth $121,000. Finally, Cornerstone Capital Management Holdings LLC. bought a new position in shares of Momenta Pharmaceuticals during the third quarter worth $135,000. Institutional investors and hedge funds own 81.62% of the company’s stock.

About Momenta Pharmaceuticals

Related posts

Leave a Comment